CompletedPhase 3NCT02063789

An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia

Studying Autoimmune thrombocytopenia

Last synced from ClinicalTrials.gov May 4, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Green Cross Corporation
Principal Investigator: Doyeun Oh, M.D., Ph.D.
CHA Bundang Medical Center
Intervention: Human immunoglobulin intravenous(drug)
Enrollment: 81 enrolled
Eligibility: 19 years · All sexes
Timeline: 2014 – 2016

Study locations (14)

Chungnam National University Hospital, Daejeon, South Korea
Daegu Catholic University Medical Center, Deagu, South Korea
Chonnam National University Hwasun Hospital, Hwasun, South Korea
Gachon University Gil Medical Center, Incheon, South Korea
Chonbuk National University Hospital, Jeonju, South Korea
Pusan National University Hospital, Pusan, South Korea
Seoul National University Bundang Hospital, Seongnam, South Korea
Asan Medical Center, Seoul, South Korea
CHA Budang Medical Center, Seoul, South Korea
Ewha Womans University Medical Center, Seoul, South Korea
Samsung Medical Center, Seoul, South Korea
Severance Hospital, Seoul, South Korea
Soon Chung Hyang University Hospital, Seoul, South Korea
VHS Medical Center, Seoul, South Korea

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02063789 on ClinicalTrials.gov

Other trials for Autoimmune thrombocytopenia

Additional recruiting or active studies for the same condition.

See all trials for Autoimmune thrombocytopenia →

← Back to all trials